Ovarian Cancer Overview

Principles

Definition

Ovarian cancer is a critical domain within oncology research dedicated to the comprehensive study of malignant neoplasms arising from ovarian, fallopian tube, or peritoneal tissues. This academic field investigates the etiology, pathogenesis, molecular subtypes, diagnostic approaches, prognostic factors, and therapeutic strategies for these diverse and often aggressive cancers, aiming to improve patient outcomes through enhanced understanding and novel interventions.

Ontological type

Therapeutic Strategies

Molecular Subtypes

Risk Factors

Key developments

Key Figures

Taxonomy-Driven Pathology era

Robert E. Scully[1] is a central figure in ovarian pathology during the Taxonomy-Driven Pathology era, with affiliations at Harvard University[2] and the University of California, San Diego[3]. His key contributions in this era include delineating Müllerian-type ovarian tumors, as demonstrated in the 1967 paper Mesonephroma of ovary, Tumor of müllerian nature related to the endometrioid carcinoma[4], which clarified histopathologic criteria and underpinned standardized taxonomy and prognosis in ovarian cancer.

Molecular and Chemotherapy Era era

Dennis J. Slamon [1] emerged as a pivotal figure during the Molecular and Chemotherapy Era (1975-2009) with affiliations at The University of Texas Southwestern Medical Center [3] and Johns Hopkins University [4], exemplified by Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer [7]. His work on the HER-2/ neu oncogene [7] clarified a molecular driver in ovarian tumors and informed trial designs and targeted regimens that integrated biology with chemotherapy, underpinning the biology-informed paradigm of this era [7]. Steven A. Narod [2] contributed through roles at the Institute of Cancer Research [5] and the University of California, San Francisco [6], and his 1994 paper A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1 [8] identified BRCA1 as a key ovarian cancer susceptibility gene. This discovery reframed risk assessment, genetic testing, and prevention strategies, enabling genetic screening and risk-reducing interventions to be integrated into translational networks that shaped ovarian cancer management in this era.

PARP-Driven Precision Era era

Michael Friedländer [1], affiliated with the Institute of Cancer Research [3] and Johns Hopkins University [4], emerges as a central figure in the PARP-driven precision era of ovarian cancer. His key contributions include the 2010 proof-of-concept trial of olaparib in BRCA1 or BRCA2 mutations and recurrent ovarian cancer [7], and the 2018 maintenance olaparib study in patients with newly diagnosed advanced ovarian cancer [6], which together helped define PARP inhibitors as targeted maintenance strategies and reinforced HRD-based patient selection in this era. Ana Oaknin [2], associated with the Institute of Cancer Research [3] and Cornell University [5], has helped shape HRD-informed strategies and PARP-inhibitor integration in ovarian cancer during this era. Her contributions include the 2018 maintenance olaparib study in newly diagnosed advanced ovarian cancer [6] and the Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial [8], illustrating the shift toward combining DNA-repair targeting with anti-angiogenic strategies to expand routine care in this era.